Clinical Research Directory
Browse clinical research sites, groups, and studies.
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
Sponsor: Hospices Civils de Lyon
Summary
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear. This observational multicenter cohort study is designed to study the occurrence of Carcinoid Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors influencing the occurrence, severity, progression and long-term survival of patients with Carcinoid Heart Disease. Basic informations and detailed diagnosis informations (oncological and cardiac parameters), are collected by professional doctors. Clinical outcomes (onset of Carcinoid Heart Disease, cardiac surgery, related death) will be followed up every year or every six/three months if clinically indicated.
Official title: Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors Carcinoid Heart Disease (CHD): An Observational French Multi-Centre Cohort Study CRUSOE - NETs (CaRdiac UltraSonic OutcomEs - NETs)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
670
Start Date
2018-04-16
Completion Date
2033-04-16
Last Updated
2024-12-03
Healthy Volunteers
No
Conditions
Interventions
Study of the occurrence of Carcinoid Heart Disease
Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease. In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease. Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease.
Locations (19)
CHU Amiens
Amiens, France
CHU Angers
Angers, France
CHU Bordeaux - Hopital Haut-Lévèque
Bordeaux, France
APHP Beaujon
Clichy, France
CHU Dijon
Dijon, France
GHICL Lille
Lille, France
Centre Oscar Lambret
Lille, France
CHRU Lille
Lille, France
Hôpital Edouard HERRIOT, Institut du Cancer - Hospices Civils de Lyon
Lyon, France
Institut Paoli-Calmettes
Marseille, France
APHP - Hopital Cochin
Paris, France
APHP - Saint Antoine
Paris, France
CHU Poitiers
Poitiers, France
CHU Reims
Reims, France
CHU Rennes
Rennes, France
Hôpital Haute Pierre
Strasbourg, France
CHU Rangueil
Toulouse, France
CHRU Tours
Tours, France
Institut Gustave Roussy
Villejuif, France